- Home
- » Tags
- » Dacomitinib
Top View
- VIZIMPRO (Dacomitinib) RATIONALE for INCLUSION in PA PROGRAM
- Recent Advances in the Management of Advanced Non–Small-Cell Lung Cancer Charu Aggarwal, MD, MPH, and Corey J
- Pfizer Oncology Analyst Call
- Dacomitinib Is an Investigational Agent and Has Not Been Approved by Any Regulatory Agency at This Time
- Vizimpro (Dacomitinib)
- Vizimpro, INN-Dacomitinib
- ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond Mark M
- Dacomitinib for Locally Advanced Or Metastatic EGFR Positive Non- Small Cell Lung Cancer – First Line
- Tyrosine Kinase Inhibitors (Tkis) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects
- Dacomitinib Potentiates the Efficacy of Conventional Chemotherapeutic
- Dacomitinib (PF-00299804) Fact Sheet
- (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- BLA 125477/ S34 ODAC Briefing Document Ramucirumab 1 FDA
- Vizimpro, INN-Dacomitinib
- Emerging Therapeutic Agents for Lung Cancer Bhagirathbhai Dholaria, William Hammond, Amanda Shreders and Yanyan Lou*
- Open Full Page
- ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Lung Cancer
- © 2021 Reachmd Page 1 of 6 Considered Standard of Care in Patients with Stage IV Non–Small-Cell Lung Cancer
- My Journey from Tyrosine Phosphorylation Inhibitors to Targeted Immune Therapy As Strategies to INAUGURAL ARTICLE Combat Cancer
- Supplementary Appendix
- Pfizer Pipeline Snapshot 4
- MAP3K1 and MAP2K4 Mutations Are Associated with Sensitivity to MEK Inhibitors in Multiple Cancer Models
- Cost-Effectiveness of Dacomitinib Vs. Gefitinib As
- Oncology Agents Policy #: Rx.01.67
- HER2-D16 Oncogenic Driver Mutation Confers Osimertinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Download PDF File
- Targeting HER2 with Trastuzumab Deruxtecan: a Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- Comparative Analysis of Drug Response and Gene Profiling Of
- 211288Orig1s000
- Oncology Dose Finding Workshop
- Blocking Both Epidermal Growth Factor Receptor and Mesenchymal-To-Epithelial Transition Pathways in EGFR-Mutated Lung Cancer
- Characterization of EGFR T790M, L792F, and C797S Mutations As
- Tyrosine Kinase Inhibitors - Oral
- Gefitinib) in a Head-To-Head Clinical Study
- Phase 1 Study of the Pan-HER Inhibitor Dacomitinib Plus the MEK1
- PHARMACY TIMES by IEHP PHARMACEUTICAL SERVICES DEPARTMENT April 1, 2019
- Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Recurrent And/Or Metastatic Esophageal Squamous Cell Carcinoma
- September 17, 2012 Jenifer Antonacci (610) 427-0369 Matti Ojanen
- Molecular Changes Associated with Acquired Resistance to Crizotinib In
- SFJ Pharma, Pfizer Collaborate for Dacomitinib Trial
- Dacomitinib (PF-00299804), a Pan-HER Inhibitor, Vs Erlotinib in Second- Or Third-Line Therapy for Advanced Non- Small Cell Lung Cancer (NSCLC)
- Dacomitinib Improves Chemosensitivity of Cisplatin‑Resistant Human Ovarian Cancer Cells
- 5.01.603 Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2
- Identification of Optimal Dosing Schedules of Dacomitinib And
- Progress in Anti-HER2 Targeted Therapy of Metastatic Lung Cancer
- Dacomitinib Is an Investigational Agent and Has Not Been Approved by Any Regulatory Agency at This Time
- And Second-Generation EGFR-Tkis Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for The
- Tyrosine Kinase Receptors in Oncology
- Therascreen EGFR RGQ PCR Kit US Instructions For